When Mounjaro stops working as well as it did

Why the plateau happens: the biology behind a slower rate of loss

One of the most common things people assume when Mounjaro slows down is that the medicine has somehow worn out or stopped working. That belief is understandable, but the evidence doesn't support it. What actually happens is that as your body weight falls, your basal metabolic rate falls with it. You burn fewer calories at rest at 90 kg than you did at 110 kg. Tirzepatide's dual action on GIP and GLP-1 receptors continues to suppress appetite and slow gastric emptying; the arithmetic of weight loss just gets harder because your body is lighter and more efficient at conserving energy. This is sometimes called metabolic adaptation, and it occurs regardless of how a person is losing weight, diet alone, surgery, or medication. The SURMOUNT-1 data showed that weight reduction was steepest in weeks one to thirty-six and then levelled into a flatter maintenance curve through week seventy-two, but participants did not regain weight while remaining on treatment at their highest tolerated dose. So a slowing rate of loss is not the same as the medicine stopping working altogether. If you are concerned about what to do when Mounjaro stops working, the reasons behind it and the appropriate next steps are worth understanding before drawing any conclusions. The two feel identical from the inside, but they are clinically different situations with different appropriate responses.

Practical factors that can blunt tirzepatide's effect over time

Beyond metabolic adaptation, there are several modifiable factors worth examining honestly. Dietary habits have a habit of creeping back toward pre-treatment patterns once the most intense nausea phase passes, portion sizes grow slightly, snacking reappears, alcohol intake normalises. Tirzepatide reduces appetite but does not eliminate hunger entirely, and the body's learned food behaviours reassert themselves gradually. Physical activity is the other lever: even modest strength training helps preserve muscle mass during weight loss, and muscle burns more energy at rest than fat tissue does. The NHS recommends maintaining both a reduced-calorie diet and increased activity alongside treatment, and the SmPC lists these as conditions of the licence rather than optional extras. There are also medication interactions worth knowing about (you can read about how tirzepatide may affect oral contraceptive absorption) though those interactions relate to the pill's efficacy rather than Mounjaro's. Finally, it is worth checking the basics: injection technique, rotation of sites, and correct pen storage all affect how much active medicine your body actually receives. A pen stored above the recommended refrigerated temperature may deliver less than the intended dose, so the NHS tirzepatide guidance and the Patient Information Leaflet are worth revisiting if you have any doubt.

What your prescriber can do, and what you should not do alone

The appropriate response to a sustained plateau depends on where you are in your titration schedule. If you have not yet reached your highest tolerated dose, a planned increase is the most straightforward clinical option; tirzepatide is licensed in the UK at 2.5, 5, 7.5, 10, 12.5, and 15 mg. Whether a dose increase is right for you involves a clinical assessment of your response and any side effects at your current dose, this is something a GPhC-registered prescriber decides after reviewing your progress, not something to do on instinct. If you are already at the highest dose you tolerate, your prescriber may discuss a structured review of dietary and activity habits, or consider whether another treatment option is more appropriate. Some people find that a brief break followed by re-initiation can reset GI tolerance and appetite response, though the evidence base for this approach is still developing, so it is a conversation for your clinical team. What is not advisable is skipping doses in the hope that a period off the medicine will make the body more responsive again, the data from SURMOUNT show that weight tends to return when treatment stops. The question of whether tirzepatide can genuinely stop responding in a pharmacological sense is one our prescribers hear often; the honest answer is that true tachyphylaxis is not a documented pattern with this medicine, but inadequate dose, lifestyle drift, and metabolic adaptation together can look exactly like it. If you are weighing up your options across the range of available treatments, that broader conversation is worth having too.

When to have a formal review, and what it involves

NICE TA1026 sets a clear benchmark: if you have not achieved at least five per cent weight loss after six months at the highest dose you can tolerate, continuing tirzepatide should be reviewed. This is not a cut-off that means treatment has failed you as a person; it is a clinical decision point designed to make sure you are on the most appropriate path. A formal review does not need to be lengthy or complicated. At nume, every repeat order is reviewed by a prescriber before it is dispensed (no repeat is automatic) which means the review process is built into how the service runs rather than something you need to chase. Bring your weight records, any observations about side effects, and an honest account of how your eating and activity have looked over recent weeks. The more complete the picture, the more useful the clinical advice. If your current provider is not offering this kind of structured check-in, it is worth asking directly. For a reference on how long each pen lasts and whether timing might be affecting your results, that detail is covered separately. You can also explore the full tirzepatide treatment overview for a broader picture, or read the most common questions our clinical team fields about ongoing treatment. When you are ready to speak to a prescriber about your current situation, starting a free consultation is the straightforward next step.